Skip to main content

Herpes Genitalis

5
Pipeline Programs
3
Companies
3
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 4 programs with unclassified modality

On Market (1)

Approved therapies currently available

GSK
VALTREXApproved
valacyclovir hydrochloride
GSK
oral1995
5M Part D

Competitive Landscape

3 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
2
ValaciclovirPhase 4Small Molecule
valacyclovir hydrochloridePhase 4
GSK
GSKLONDON, United Kingdom
1 program
1
valacyclovir hydrochloridePHASE_41 trial
Active Trials
NCT00079911Terminated7Est. Oct 2004
Astellas
AstellasChina - Shenyang
2 programs
1
1
ASP2151Phase 21 trial
ASP2151Phase 11 trial
Active Trials
NCT02852876Completed72Est. Dec 2005
NCT00486200Completed695Est. Aug 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKvalacyclovir hydrochloride
AstellasASP2151
AstellasASP2151

Clinical Trials (3)

Total enrollment: 774 patients across 3 trials

NCT00079911GSKvalacyclovir hydrochloride

A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons

Start: Mar 2004Est. completion: Oct 20047 patients
Phase 4Terminated

A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

Start: Jun 2007Est. completion: Aug 2008695 patients
Phase 2Completed

Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food

Start: Sep 2005Est. completion: Dec 200572 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.